Telesis Bio Inc
NASDAQ:TBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Telesis Bio Inc
Accounts Payable
Telesis Bio Inc
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Telesis Bio Inc
NASDAQ:TBIO
|
Accounts Payable
$3.3m
|
CAGR 3-Years
40%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Accounts Payable
$3.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
11%
|
CAGR 10-Years
16%
|
|
|
Danaher Corp
NYSE:DHR
|
Accounts Payable
$1.8B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
3%
|
|
|
Waters Corp
NYSE:WAT
|
Accounts Payable
$103.8m
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
4%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Accounts Payable
$602m
|
CAGR 3-Years
4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Accounts Payable
$3.8B
|
CAGR 3-Years
4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
38%
|
|
Telesis Bio Inc
Glance View
Telesis Bio, Inc. engages in research and development of genomic tools for biomedical and industrial applications. The company is headquartered in San Diego, California and currently employs 212 full-time employees. The company went IPO on 2021-06-18. Its synthetic biology solution addresses bottlenecks across the multi-step process of building DNA and mRNA, as well as the limitations of existing solutions that prevent the building of DNA and mRNA at a useable scale. Its BioXp system is an end-to-end automated workstation. The firm's products include BioXp systems, including BioXp 3250 system, BioXp kits for generating a range of synthetic DNA and mRNA, and benchtop reagents that complement the automated synthetic biology workflow applications and workflow solutions. The company has launched eight BioXp kits, three benchtop reagent kits, and various other synthetic biology products, including 14 SARS-CoV-2 full-length genomes and RNA controls, as well as its Vmax X2 cells. The company has placed approximately 200 BioXp systems globally.
See Also
What is Telesis Bio Inc's Accounts Payable?
Accounts Payable
3.3m
USD
Based on the financial report for Dec 31, 2023, Telesis Bio Inc's Accounts Payable amounts to 3.3m USD.
What is Telesis Bio Inc's Accounts Payable growth rate?
Accounts Payable CAGR 3Y
40%
Over the last year, the Accounts Payable growth was 154%. The average annual Accounts Payable growth rates for Telesis Bio Inc have been 40% over the past three years .
